Technical Analysis for NGM - NGM Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 16.28 -1.39% -0.23
NGM closed down 1.39 percent on Monday, October 19, 2020, on 79 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical NGM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
20 DMA Resistance Bearish -1.39%
Hammer Candlestick Bullish -0.91%
NR7 Range Contraction -0.91%
Down 3 Days in a Row Weakness -0.91%
Down 4 Days in a Row Weakness -0.91%
Down 5 Days in a Row Weakness -0.91%
Fell Below 20 DMA Bearish -2.05%
Down 3 Days in a Row Weakness -2.05%
Down 4 Days in a Row Weakness -2.05%
Older End-of-Day Gignals for NGM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
20 DMA Resistance about 9 hours ago
20 DMA Support about 9 hours ago
Up 2% about 9 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Diabetes Monoclonal Antibodies Obesity Age Related Macular Degeneration Treatment Of Obesity

Is NGM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.95
52 Week Low 9.245
Average Volume 162,695
200-Day Moving Average 17.83
50-Day Moving Average 17.58
20-Day Moving Average 16.56
10-Day Moving Average 16.96
Average True Range 0.83
ADX 16.04
+DI 16.13
-DI 23.26
Chandelier Exit (Long, 3 ATRs ) 16.87
Chandelier Exit (Short, 3 ATRs ) 17.43
Upper Bollinger Band 17.80
Lower Bollinger Band 15.33
Percent B (%b) 0.39
BandWidth 14.94
MACD Line -0.28
MACD Signal Line -0.28
MACD Histogram 0.0033
Fundamentals Value
Market Cap 1.12 Billion
Num Shares 68.8 Million
EPS -0.46
Price-to-Earnings (P/E) Ratio -35.62
Price-to-Sales 12.75
Price-to-Book 4.10
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.34
Resistance 3 (R3) 17.45 17.21 17.16
Resistance 2 (R2) 17.21 16.94 17.15 17.10
Resistance 1 (R1) 16.74 16.77 16.62 16.63 17.04
Pivot Point 16.50 16.50 16.44 16.45 16.50
Support 1 (S1) 16.04 16.23 15.92 15.93 15.52
Support 2 (S2) 15.80 16.07 15.74 15.46
Support 3 (S3) 15.33 15.80 15.40
Support 4 (S4) 15.22